UniSuper Management 13F: Cuts BSX Stake by $25M
Key Points
- UniSuper Management's recent filing disclosed a reduction of 579,768 shares in Boston Scientific, a move valued at approximately $8.2 million.
- UniSuper Management held 187,299 $BSX shares at quarter end, down 75.58% from the prior quarter.
- Boston Scientific's stock recently traded at about $45.6, which is significantly below its 52-week high of $105.65.
- The firm holds a 0.07% share of its total reported value of $11.5 billion in this position, ranking 53rd among its holdings.
Get Boston Scientific text alerts
We text you when insiders, Congress, analysts or big funds move on $BSX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
On October 26, 2026, UniSuper Management cut its stake in Boston Scientific Corporation (BSX) by 579,768 shares, bringing its total to 187,299 shares. This reduction is valued at about $8.2 million, according to the fund's latest Form 13F filing with the SEC.
BSX
Boston Scientific Corporation
UniSuper Management vs. the S&P 500
Hypothetical returns from UniSuper Management's disclosed trades, not real profit or advice. How we model this.
What Changed in UniSuper Management's Boston Scientific Position
UniSuper Management's reported value in Boston Scientific decreased by approximately $25.3 million, reflecting a 75.6% cut in its position. The fund now holds a total of 187,299 shares, making up 0.07% of its overall portfolio, which is valued at $11.5 billion.
Where Boston Scientific Fits in UniSuper Management's Portfolio
Boston Scientific ranks 53rd in UniSuper's portfolio. The significant reduction in shares indicates a strategic shift, as the position is now much smaller compared to previous holdings.
Boston Scientific Corporation Stock Down 0.2%
Boston Scientific shares recently traded around $45.6, about equal to the closing price of $45.58 on October 26, 2026. The stock is currently below its 200-day moving average and significantly below its 52-week high of $105.65, indicating potential challenges in the market.
Recent Earnings
For the trailing twelve months, Boston Scientific reported revenue of approximately $20.99 billion and an earnings per share (EPS) of $2.47. The company is set to release its next earnings report on October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Recently, several insiders bought shares of Boston Scientific. CEO Michael F. Mahoney purchased 186,240 shares at an average price of $48.33 on August 3, 2026, totaling about $9 million. Director David C. Habiger also bought shares on August 4 and August 5, while Director Susan E. Morano made a purchase on August 25.
Analysts Set New Price Targets
On October 26, 2026, Stifel maintained a "Buy" rating for Boston Scientific, setting a price target of $55.0, down from $60.0. Other firms, including Wells Fargo and Citigroup, have maintained their ratings with targets around $48.0. The consensus recommendation for Boston Scientific remains a "Buy" with a mean price target of $57.82.
About Boston Scientific
Boston Scientific Corporation develops and manufactures medical devices for various specialties, including cardiovascular and med-surg. The company is headquartered in Marlborough, MA, and employs around 59,000 people. This position cut by UniSuper reflects a broader trend in their investment strategy.
Bottom Line
Investors should watch the upcoming earnings report on October 28, 2026, for insights into Boston Scientific's performance. UniSuper's significant cut in its position may indicate a reevaluation of its investment in the company.
Related Filing Alerts
Source: UniSuper Management's 13F filing on $BSX (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts